Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Avai BioAVAI +12.57%24 Revenue per Share is $0.00 as of Dec. 2025. GuruFocus rates AVAI with a GF Score™ of 24/100. The stock has 3 warning signs investors should review. Among 2,578 Software companies, Avai Bio ranks worse than 38789.72% on this metric.
Avai Bio's revenue per share for the
three
months ended in Dec. 2025 was $0.00.
Avai Bio's revenue per share for the trailing twelve months (TTM) ended in Dec. 2025 was $0.00.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get other companies' revenue growth rate.
The historical rank and industry rank for Avai Bio's Revenue per Share or its related term are showing as below:
During the past 8 years, Avai Bio's highest 3-Year average Revenue Per Share Growth Rate was -41.50% per year. The lowest was -41.50% per year. And the median was -41.50% per year.
AVAI's 3-Year Revenue Growth Rate is not ranked *
in the Software industry.
Industry Median: 6.7 * Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
Avai Bio (OTCPK:AVAI) Revenue per Share Explanation
In ranking the predictability, companies with more consistent revenue and earnings growth are ranked high with predictability.
Peter Lynch categorized companies according to their revenue growth:
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
Avai Bio Revenue per Share Related Terms
Avai Bio Revenue per Share Historical Data
* Premium members only.
The historical data trend for Avai Bio's Revenue per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
AVAI vs IPM, CRMZ, AWRE: Revenue per Share Comparison
For the Software - Application subindustry, Avai Bio's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Avai Bio PS Ratio vs Software Industry
For the Software industry and Technology sector, Avai Bio's PS Ratio distribution charts can be found below:
* The bar in red indicates where Avai Bio's PS Ratio falls into.
Revenue per Share is the amount of Revenue per outstanding share of the company's stock.
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Avai Bio's Revenue Per Share for the fiscal year that ended in Mar. 2025 is calculated as
Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.00
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Avai Bio (AVAI) has a Revenue per Share of $0.00 as of Dec. 2025. Revenue per share equals the per-share value of a company's sales. View historical data on Avai Bio and its competitors. According to the industry distribution chart, Avai Bio ranks #999999 out of 2578 companies in the Software industry.
Is Avai Bio's Revenue per Share too high?
Avai Bio's current Revenue per Share is $0.00. Based on the distribution chart, Avai Bio ranks #999999 out of 2578 companies in the Software industry, which is in the bottom quartile relative to peers. Overall, Avai Bio has a GF Score™ of 24/100, reflecting its overall financial health beyond just this single metric.
How does Avai Bio's Revenue per Share compare to IPM and CRMZ?
According to the Software industry distribution chart, Avai Bio ranks #999999 out of 2578 companies for Revenue per Share. This places Avai Bio in the lower half of its industry. The industry median Revenue per Share is 6.70. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue per Share for a Software company?
The median Revenue per Share among Software companies is 6.70, based on 2,578 companies in the industry. Companies in the top quartile (top 25%) have a Revenue per Share significantly above this median, while those in the bottom quartile fall well below. However, Revenue per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue per Share mean?
A high Revenue per Share can signal that a stock is expensive relative to its fundamentals. Revenue per share equals the per-share value of a company's sales. View historical data on Avai Bio and its competitors. For the Software industry, the median Revenue per Share is 6.70 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Avai Bio's current Revenue per Share is $0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Avai Bio stock overvalued right now?
Avai Bio (AVAI) has a current Revenue per Share of $0.00. The current Revenue per Share is $0.00. Avai Bio's overall GF Score™ is 24/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue per Share calculated?
Revenue per Share is calculated from a company's financial statements. For Avai Bio (AVAI), the current Revenue per Share is $0.00 as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Avai Bio Inc is a biotechnology company focused on identifying genetically modified cell lines, and through joint venture and licensing agreements, developing cell-based therapies. The company has two development programs in its cellular therapies pipeline, a diabetes development program to advance a treatment for type 1 and type 2 insulin-dependent diabetes, and an ?-Klotho protein development program to advance therapies for age-related diseases and anti-aging treatments.
24GF Score
Get the complete analysis for AVAI
Revenue per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
AVAI has been successfully added to your 
